amdizatinib

Amdizatinib (HMPL-689) is a highly selective, potent, and orally available small molecule inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) isoform. Developed by HUTCHMED, it is designed to target B-cell malignancies by inhibiting the PI3Kδ signaling pathway, which is critical for the proliferation, survival, and migration of malignant B-cells. Unlike pan-PI3K inhibitors, amdizatinib's selectivity for the delta isoform aims to minimize off-target toxicities associated with the alpha and beta isoforms, such as hyperglycemia and gastrointestinal issues. It is currently being investigated in various B-cell lymphomas, including follicular lymphoma, marginal zone lymphoma, and chronic lymphocytic leukemia, with registration-intent trials underway in China.

Other names

amdizatinib